

State of Oklahoma Oklahoma Health Care Authority Istodax® (Romidepsin) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Information	
Physician billing (HCPCS code:	ode:) Start Date (or date of next dose):	
Dose:	Regimen:	
	Billing Provider Informa	ation
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
	Prescriber Information	on
Prescriber NPI:	Prescriber Name	e:
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
B. Does member have relaps 2. Please indicate the diagnosis ar Primary Cutaneous Lym A. Will romidepsin be us Anaplastic Large Cell Ly A. Does member have m B. Will romidepsin be us Peripheral T-Cell Lymph T-Cell Lymphoma, Extra A. Does member have recombination chemoth	s a single-agent? Yes Nosed or refractory disease? Yesnd information: uphomas – Mycosis Fungoides ued as primary treatment? Yes umphoma (ALCL), Primary Cuta nultifocal lesions or regional node ued as primary treatment? Yes uma (PTCL) nodal NK/T-Cell Lymphoma, Na elapsed/refractory disease follow uerapy regimen not previously use above, please indicate diagnos	No (MF)/Sézary Syndrome (SS)No aneous es? YesNoNo asal Type ring additional therapy with an alternate ed? YesNo sis:
For Continued Authorization: 1. Date of last dose: 2. Does member have any evidence 3. Has the member experienced and If yes, please specify adverses.	ny adverse drug reactions related	
	is medically necessary and all info	Date:
knowledge. Please do not send in ch complete this form in full will result in pr		ill be requested if necessary. Failure to

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.